Inhibikase Therapeutics Inc
NASDAQ:IKT

Watchlist Manager
Inhibikase Therapeutics Inc Logo
Inhibikase Therapeutics Inc
NASDAQ:IKT
Watchlist
Price: 1.98 USD 2.59% Market Closed
Market Cap: 147.2m USD

Intrinsic Value

IKT doesn't have a meaningful market cap.

The intrinsic value of one IKT stock under the Base Case scenario is 1.25 USD. Compared to the current market price of 1.98 USD, Inhibikase Therapeutics Inc is Overvalued by 37%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

IKT Intrinsic Value
1.25 USD
Overvaluation 37%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Inhibikase Therapeutics Inc

What is Valuation History?
Compare IKT to

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about IKT?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Inhibikase Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Inhibikase Therapeutics Inc

Current Assets 94.2m
Cash & Short-Term Investments 93.2m
Other Current Assets 984.5k
Non-Current Assets 116.5k
PP&E 116.6k
Other Non-Current Assets -100
Efficiency

Free Cash Flow Analysis
Inhibikase Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Inhibikase Therapeutics Inc

Revenue
0 USD
Operating Expenses
-38.4m USD
Operating Income
-38.4m USD
Other Expenses
1.9m USD
Net Income
-36.5m USD
Fundamental Scores

IKT Profitability Score
Profitability Due Diligence

Inhibikase Therapeutics Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

Exceptional ROIC
ROIC is Increasing
Low 3Y Average Gross Margin
Negative 3Y Average Net Margin
34/100
Profitability
Score

Inhibikase Therapeutics Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

IKT Solvency Score
Solvency Due Diligence

Inhibikase Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Inhibikase Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IKT Price Targets Summary
Inhibikase Therapeutics Inc

Wall Street analysts forecast IKT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IKT is 8.16 USD with a low forecast of 8.08 USD and a high forecast of 8.4 USD.

Lowest
Price Target
8.08 USD
308% Upside
Average
Price Target
8.16 USD
312% Upside
Highest
Price Target
8.4 USD
324% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Inhibikase Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for IKT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

IKT Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one IKT stock?

The intrinsic value of one IKT stock under the Base Case scenario is 1.25 USD.

Is IKT stock undervalued or overvalued?

Compared to the current market price of 1.98 USD, Inhibikase Therapeutics Inc is Overvalued by 37%.

Back to Top